康希诺生物：曼海欣 获得《药品补充申请批准通知书》

Core Viewpoint - The company, CanSino Biologics (06185), has received approval from the National Medical Products Administration for an expanded age range for its meningococcal polysaccharide conjugate vaccine, MCV4 (brand name: Manhaixin), now applicable for children aged 3 months to 6 years [1] Group 1 - The approval allows the vaccine's usage to extend from children aged 3 months to 3 years (47 months) to now include children up to 6 years (83 months) [1] - Manhaixin is the first quadrivalent meningococcal conjugate vaccine product in China, addressing the gap in high-end vaccines in the country and reducing the disparity with developed nations [1] - The vaccine provides a superior solution for the prevention of meningococcal disease in children aged 6 years and below, showcasing strong market performance and increasing market share due to its innovative advantages [1]